Skip to content

Video: Combined Phacoemulsification and ELIOS for Medication Reduction

Antonio Moreno-Valladares, MD, PhD, discusses a recent real-world study of 12-month medication reduction outcomes for patients who have undergone a combined phacoemulsification and ELIOS excimer laser procedure. He describes the parameters of this multicenter study, which followed 112 patients with mild-to-moderate glaucoma and a cataract.

Share This Story

Latest News

Join Us for a Symposium During EGS in Dublin

Elios Vision will be hosting a symposium, “Excimer lasers in glaucoma: More than meets the eye,” during the EGS congress in Dublin.

Elios Vision announces collaboration with the International Glaucoma Surgical Registry

Elios Vision will be collaborating with the ISGR, an open-access tool which enables surgeons to compare outcomes with other centres.
Elios Vision logo

Elios Vision achieves three new pipeline milestones

Elios announced enrollment completion in their U.S. pivotal trial, the expansion of the U.S. pre-launch team, and continued commercial uptake in Europe.
×

Site for Healthcare Professionals Only

You are about to access Elios Vision’s online platform for healthcare professionals outside of the United States. This platform is intended to provide general product information for education and illustration purposes. It is not intended to provide information to the general public or medical advice.

As product information, availability, indication, and trade names may vary from country to country, the content of this site may not be fully in-line with the approved or cleared product information in the country you are accessing from. Unless stated otherwise for specific product or event pages, the content on this site is based on the regulatory and legal principles applicable to the United Kingdom.

By closing this popup, I confirm that:

  • I understand that this platform is directed to Healthcare Professionals only and that I am a licensed Healthcare Professional.
  • I have read and agree to Elios Vision’s terms and conditions and privacy policy.